VCM eradication therapy for penicillin allergy

Phase 2

Recruiting

• Conditions: Helicobacter pylori infection; Helicobacter pylori

• Registration Number: JPRN-jRCTs031200171
• Lead Sponsor: Sue Soichiro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-26
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients infected with Helicobacter pylori. Patients allergic to penicillin. Patients who give a written informed consent.

Exclusion Criteria

Past history of Helicobacter pylori eradication therapy. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy (vonoprazan, clarithromycin, or metronidazole).
Patients using atazanavir, rilpivirine, pimozide, ergotamine, suvorexant, lomitapide mesylate, tadalafil, ticagrelor, ibrutinib, asuna previr, ivavradine, venetoclax, lurasidone hydrochloride, anamorelin hydrochloride, finerenone, or isavuconazonium sulfate. Patients using colchicine with liver dysfunction or renal dysfunction. Patients with cerebrospinal disease. Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction. Patients who are disqualified for the study by physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified